SCGB1A1 and cystic fibrosis: CC16 protein and its truncated C-terminal peptide have been proposed to treat a variety of inflammatory lung diseases (i.e., neonatal respiratory distress syndrome (nRDS), acute respiratory distress syndrome (ARDS), asthma and CF) [53].